Profile data is unavailable for this security.
About the company
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
- Revenue in JPY (TTM)874.12m
- Net income in JPY-5.23bn
- Incorporated1999
- Employees55.00
- LocationAnGes IncSaito Bio-Incubator, 7-7-15, Saito-AsagiIBARAKI-SHI 567-0085JapanJPN
- Phone+81 357302641
- Websitehttps://www.anges.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nyrada Inc | 277.09m | -524.73m | 21.22bn | -- | -- | 47.17 | -- | 76.58 | -0.0243 | -0.0243 | 0.0128 | 0.017 | 0.4566 | -- | -- | -- | -86.47 | -48.87 | -112.02 | -53.88 | -- | -- | -189.37 | -195.83 | -- | -- | 0.00 | -- | -24.81 | 18.93 | -248.28 | -- | -- | -- |
| Pacific Edge Ltd | 1.55bn | -3.19bn | 21.66bn | 0.00 | -- | 8.36 | -- | 13.96 | -0.0409 | -0.0409 | 0.02 | 0.0263 | 0.3935 | -- | 3.78 | -- | -80.80 | -36.39 | -98.90 | -40.47 | -- | -- | -205.33 | -142.52 | 3.83 | -- | 0.0795 | -- | -8.62 | 37.97 | -1.36 | -- | 47.39 | -- |
| B&K Corp Ltd | 5.77m | -4.04bn | 21.84bn | 100.00 | -- | 11.69 | -- | 3,786.68 | -1.76 | -1.76 | 0.0025 | 0.8126 | -- | -- | -- | -- | -- | -- | -- | -- | 92.34 | -- | -69,968.59 | -- | -- | -- | 0.0371 | -- | -44.70 | -- | -101.78 | -- | -- | -- |
| AnGes Inc | 874.12m | -5.23bn | 23.74bn | 55.00 | -- | 7.59 | -- | 27.16 | -15.21 | -15.21 | 2.46 | 7.91 | 0.1735 | 0.3487 | 8.45 | -- | -103.74 | -49.52 | -189.41 | -59.16 | 36.65 | 31.53 | -597.83 | -3,839.32 | 1.18 | -23.87 | 0.0174 | -- | 35.81 | 85.31 | 81.42 | -- | -29.27 | -- |
Data as of Feb 13 2026. Currency figures normalised to AnGes Inc's reporting currency: Japanese Yen JPY
3.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Athos Capital Ltd.as of 21 Aug 2025 | 11.32m | 2.92% |
| Simplex Asset Management Co., Ltd.as of 08 Jan 2026 | 909.80k | 0.24% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 83.20k | 0.02% |
| SPARX Asset Management Co., Ltd.as of 11 Mar 2024 | 40.30k | 0.01% |
| Dimensional Fund Advisors LPas of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
